Endocrinol Metab.  2024 Dec;39(6):899-907. 10.3803/EnM.2024.2046.

A Neglected Point: Frailty in Older Adults with Differentiated Thyroid Cancer

• Coskun M
• Cataltepe E
• Varan HD
• Ceker E
• Bektas Y
• Kuscu Y
• Yalcin MM
• Akturk M
• Toruner FB
• Karakoc MA
• Altinova AE

• KMID: 2562718
• DOI: http://doi.org/10.3803/EnM.2024.2046

Abstract

Background
This study investigated the risk of frailty in older adults with differentiated thyroid cancer (DTC) and the effect of thyroid- stimulating hormone (TSH) levels on frailty.
Methods
This single-center, cross-sectional study included 70 DTC patients aged ≥60 years with stable TSH levels during the previous year while receiving levothyroxine. Frailty was assessed using the fried frailty phenotype (FFP). Anterior thigh muscle thickness was measured by ultrasound, and the sonographic thigh adjustment ratio (STAR) index was calculated. Muscle strength was measured using a hand dynamometer. Physical activity was determined by the physical activity scale for the elderly (PASE).
Results
The median (interquartile range) age and follow-up time were 65 years (62 to 71) and 11 years (7.0 to 14.2), respectively. The median TSH level was 1.10 μIU/mL (0.49 to 1.62), and 58.6% of patients were prefrail/frail. Muscle mass and strength were reduced in 35.7% and 17.2% of patients, respectively. TSH levels were lower in those with prefrailty/frailty (P=0.002), low muscle mass (P=0.014), and low strength (P=0.037) than in their normal counterparts. TSH levels correlated negatively with FFP (P= 0.001) and positively with the STAR index (P=0.034). TSH below 1.325 μIU/mL was associated with an increased frailty risk (area under the curve=0.719; P=0.001). Low TSH, female sex, low handgrip strength, and low PASE leisure time scores emerged as independent predictors of frailty (P<0.05).
Conclusion
Older adults with lower TSH levels due to DTC are at high frailty risk and have low muscle mass and strength. Therefore, TSH targets should be set based on a comprehensive evaluation with consideration of the risk-benefit ratio.

Keyword

Differentiated thyroid cancer; Thyroid-stimulating hormone level; Frailty; Muscle mass; Muscle strength

Figure

• 

  Fig. 1. Receiver operating characteristic (ROC) analysis of thyroid-stimulating hormone (TSH) levels for the risk of frailty. AUC, area under the curve.

• 

Reference

1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26:1–133.

2. Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30:1856–83.

3. Cesari M, Calvani R, Marzetti E. Frailty in older persons. Clin Geriatr Med. 2017; 33:293–303.

4. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013; 381:752–62.

5. Kamwa V, Welch C, Hassan-Smith ZK. The endocrinology of sarcopenia and frailty. Minerva Endocrinol (Torino). 2021; 46:453–68.

6. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56:M146–56.

7. Virgini VS, Rodondi N, Cawthon PM, Harrison SL, Hoffman AR, Orwoll ES, et al. Subclinical thyroid dysfunction and frailty among older men. J Clin Endocrinol Metab. 2015; 100:4524–32.

8. Varan HD, Deniz O, Coteli S, Dogrul RT, Kizilarslanoglu MC, Goker B. Validity and reliability of Fried frailty phenotype in Turkish population. Turk J Med Sci. 2022; 52:524–7.

9. Wang X, Hu J, Wu D. Risk factors for frailty in older adults. Medicine (Baltimore). 2022; 101:e30169.

10. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39:412–23.

11. Sayer AA, Cruz-Jentoft A. Sarcopenia definition, diagnosis and treatment: consensus is growing. Age Ageing. 2022; 51:afac220.

12. Lee JC, Song BS, Kang YM, Kim YR, Kang YE, Lee JH, et al. Effect of thyroid-stimulating hormone suppression on muscle function after total thyroidectomy in patients with thyroid cancer. Front Endocrinol (Lausanne). 2021; 12:769074.

13. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48:16–31.

14. Kara M, Kaymak B, Ata AM, Ozkal O, Kara O, Baki A, et al. STAR-sonographic thigh adjustment ratio: a golden formula for the diagnosis of sarcopenia. Am J Phys Med Rehabil. 2020; 99:902–8.

15. Gungen C, Ertan T, Eker E, Yasar R, Engin F. Reliability and validity of the standardized Mini Mental State Examination in the diagnosis of mild dementia in Turkish population. Turk Psikiyatri Derg. 2002; 13:273–81.

16. Sarikaya D, Halil M, Kuyumcu ME, Kilic MK, Yesil Y, Kara O, et al. Mini nutritional assessment test long and short form are valid screening tools in Turkish older adults. Arch Gerontol Geriatr. 2015; 61:56–60.

17. Durmaz B, Soysal P, Ellidokuz H, Isik AT. Validity and reliability of geriatric depression scale-15 (short form) in Turkish older adults. North Clin Istanb. 2018; 5:216–20.

18. Arik G, Varan HD, Yavuz BB, Karabulut E, Kara O, Kilic MK, et al. Validation of Katz index of independence in activities of daily living in Turkish older adults. Arch Gerontol Geriatr. 2015; 61:344–50.

19. Isik EI, Yilmaz S, Uysal I, Basar S. Adaptation of the Lawton instrumental activities of daily living scale to Turkish: validity and reliability study. Ann Geriatr Med Res. 2020; 24:35–40.

20. Ayvat E, Kilinc M, Kirdi N. The Turkish version of the physical activity scale for the elderly (PASE): its cultural adaptation, validation, and reliability. Turk J Med Sci. 2017; 47:908–15.

21. de Oliveira Chachamovitz DS, dos Santos Vigario P, Nogueira Cordeiro MF, de Castro CL, Vaisman M, dos Santos Teixeira Pde F. Quality of life, muscle strength, and fatigue perception in patients on suppressive therapy with levothyroxine for differentiated thyroid carcinoma. Am J Clin Oncol. 2013; 36:354–61.

22. Polyzos SA, Margioris AN. Sarcopenic obesity. Hormones (Athens). 2018; 17:321–31.

23. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018; 14:513–37.

24. Atkins JL, Wannamathee SG. Sarcopenic obesity in ageing: cardiovascular outcomes and mortality. Br J Nutr. 2020; 124:1102–13.

25. Yang M, Hu M, Zhang Y, Jia S, Sun X, Zhao W, et al. Sarcopenic obesity is associated with frailty among community-dwelling older adults: findings from the WCHAT study. BMC Geriatr. 2022; 22:863.

26. Frisoli A Jr, Duque G, Paes AT, Diniz AR, Lima E, Azevedo E, et al. Sarcopenic obesity definitions and their associations with physical frailty in older Brazilian adults: data from the SARCOS study. Arch Endocrinol Metab. 2023; 67:361–71.

27. Clegg A, Hassan-Smith Z. Frailty and the endocrine system. Lancet Diabetes Endocrinol. 2018; 6:743–52.

28. Veronese N, Fernando-Watutantrige S, Maggi S, Noale M, Stubbs B, Incalzi RA, et al. Serum thyroid-stimulating hormone levels and frailty in the elderly: the Progetto Veneto Anziani Study. Rejuvenation Res. 2017; 20:165–72.

29. Park C, Ko FC. The science of frailty: sex differences. Clin Geriatr Med. 2021; 37:625–38.

30. Castrejon-Perez RC, Gutierrez-Robledo LM, Cesari M, Perez-Zepeda MU. Diabetes mellitus, hypertension and frailty: a population-based, cross-sectional study of Mexican older adults. Geriatr Gerontol Int. 2017; 17:925–30.

31. Angulo J, El Assar M, Alvarez-Bustos A, Rodriguez-Manas L. Physical activity and exercise: strategies to manage frailty. Redox Biol. 2020; 35:101513.

32. Marzetti E, Calvani R, Tosato M, Cesari M, Di Bari M, Cherubini A, et al. Physical activity and exercise as countermeasures to physical frailty and sarcopenia. Aging Clin Exp Res. 2017; 29:35–42.

33. Bano A, Chaker L, Schoufour J, Ikram MA, Kavousi M, Franco OH, et al. High circulating free thyroxine levels may increase the risk of frailty: the Rotterdam study. J Clin Endocrinol Metab. 2018; 103:328–35.

34. Do Cao C, Wemeau JL. Risk-benefit ratio for TSH-suppressive levothyroxine therapy in differentiated thyroid cancer. Ann Endocrinol (Paris). 2015; 76(1 Suppl 1):1S47–52.

35. Lee YJ, Kim MH, Lim DJ, Lee JM, Chang SA, Lee J. Exploring the association between thyroid function and frailty: insights from representative Korean data. Endocrinol Metab (Seoul). 2023; 38:729–38.